Advertisement

Prevalence and Disparities in Influenza Vaccination Among Patients With COPD in the United States

Published:October 27, 2020DOI:https://doi.org/10.1016/j.chest.2020.10.058
      COPD is currently the fourth leading cause of death in the United States and worldwide.
      • Mokdad A.H.
      • Ballestros K.
      • Echko M.
      • et al.
      The State of US Health, 1990-2016: Burden of diseases, injuries, and risk factors among US states.
      Influenza-related infections are among the main causes of COPD exacerbations, hospitalizations, and mortality, all of which have been proven to be diminished with influenza vaccination.
      • Wongsurakiat P.
      • Maranetra K.N.
      • Wasi C.
      • Kositanont U.
      • Dejsomritrutai W.
      • Charoenratanakul S.
      Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study.
      ,
      • Mulpuru S.
      • Li L.
      • Ye L.
      • et al.
      Effectiveness of influenza vaccination on hospitalizations and risk factors for severe outcomes in hospitalized patients with COPD.
      To read this article in full you will need to make a payment
      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Mokdad A.H.
        • Ballestros K.
        • Echko M.
        • et al.
        The State of US Health, 1990-2016: Burden of diseases, injuries, and risk factors among US states.
        JAMA. 2018; 319: 1444-1472
        • Wongsurakiat P.
        • Maranetra K.N.
        • Wasi C.
        • Kositanont U.
        • Dejsomritrutai W.
        • Charoenratanakul S.
        Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study.
        Chest. 2004; 125: 2011-2020
        • Mulpuru S.
        • Li L.
        • Ye L.
        • et al.
        Effectiveness of influenza vaccination on hospitalizations and risk factors for severe outcomes in hospitalized patients with COPD.
        Chest. 2019; 155: 69-78
        • Bekkat-Berkani R.
        • Wilkinson T.
        • Buchy P.
        • et al.
        Seasonal influenza vaccination in patients with COPD: a systematic literature review.
        BMC Pulm Med. 2017; 17: 79
        • Trethewey S.P.
        • Patel N.
        • Turner A.M.
        Interventions to increase the rate of influenza and pneumococcal vaccination in patients with chronic obstructive pulmonary disease: a scoping review.
        Medicina (Kaunas). 2019; 55
      1. Medical Expenditure Panel Survey.
        (Accessed April 1, 2020.)
        • Ford E.S.
        • Croft J.B.
        • Mannino D.M.
        • Wheaton A.G.
        • Zhang X.
        • Giles W.H.
        COPD surveillance—United States, 1999-2011.
        Chest. 2013; 144: 284-305
        • Miller J.D.
        • Foster T.
        • Boulanger L.
        • et al.
        Direct costs of COPD in the U.S.: an analysis of Medical Expenditure Panel Survey (MEPS) data.
        COPD. 2005; 2: 311-318
        • Zhao Q.
        • Meng M.
        • Kumar R.
        • et al.
        The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis.
        J Med Virol. 2020; ([Published online ahead of print April 15, 2020])https://doi.org/10.1002/jmv.25889
        • Wang D.
        • Hu B.
        • Hu C.
        • et al.
        Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.
        JAMA. 2020; 323: 1061-1069